The National Institute for Health and Care Excellence for England and Wales (NICE), has reversed an earlier negative decision and...
Novartis announced that the top-line results from the Phase III COMPLEMENT 2 study showed that treatment with Arzerra (ofatumumab) plus...
Genmab announces it is removing Arzerra from the chronic lymphocytic leukaemia market outside the US.
GSK announced an agreement with Novartis Pharma AG, a subsidiary of Novartis AG, to divest its rights in Arzerra (ofatumumab)...
The European Commission (EC) has granted marketing authorisation for a new indication for the use of Arzerra (ofatumumab), from Glaxo...
The FDA has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra (ofatumumab), from Glaxo Smith Kline/Genmab,...
GlaxoSmithKline plc and Genmab A/S announced that the Phase III study (ORCHARRD) of ofatumumab (Arzerra) plus chemotherapy versus rituximab plus...
Phase III data published in The Lancet showed that treatment with Arzerra (ofatumumab), from Novartis, plus chlorambucil, a chemotherapy, resulted...
Glaxo Smith Kline and Genmab have submitted a variation to the Marketing Authorisation to the European Medicines Agency for the...